{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-050223","form_type":"8-K","ticker":"PURE","cik":"0001006028","company_name":"PURE BIOSCIENCE, INC.","filed_at":"2024-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.330446+00:00","generated_at":"2026-05-29T02:42:06.471885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)","bullets":["Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.","Net loss narrowed to $689K from $735K YoY; net loss per share unchanged at ($0.01).","Excluding share-based compensation, net loss was $632K vs $655K YoY.","CEO cites unexpected interruption in product flow to a major customer and lack of replacement revenue as reasons for the decline."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-050223","json":"https://secwatch.observer/filing/0001493152-24-050223.json","markdown":"https://secwatch.observer/filing/0001493152-24-050223.md","text":"https://secwatch.observer/filing/0001493152-24-050223.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/0001493152-24-050223-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006028/000149315224050223/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:42:06.471885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}